Arginine vasopressin deficiency (AVP-D, central diabetes insipidus)

What changes during this transition

Arginine vasopressin deficiency is the editorially distinct entry in the substrate program: it is the rare disease where the standard-of-care intervention IS a peptide therapy. Desmopressin (DDAVP) is a synthetic V2-selective arginine vasopressin analog — a peptide drug FDA-approved since 1978 with a half-century safety record and an established place at the center of every AVP-D treatment algorithm worldwide. The substrate framing for AVP-D therefore needs to do two things at once: honor the reality that 'peptides have no role here' would be wrong (desmopressin DOES have a role and IS a peptide), AND honor the reality that the community peptide candidates users may ask about — BPC-157, NMN, the GH-axis stack (CJC-1295, tesamorelin, ipamorelin) — are not appropriate adjuncts to desmopressin therapy and do not deserve elevation as discovery options. Both are true simultaneously. The 2022 international consensus nomenclature change matters for patient-side communication. The renaming of central diabetes insipidus to arginine vasopressin deficiency (AVP-D), and nephrogenic DI to arginine vasopressin resistance (AVP-R), came from a multi-society consensus specifically to reduce the documented hospital-setting confusion with diabetes mellitus — confusion that has caused medication errors (insulin given when desmopressin was charted), inappropriate NPO-period fluid management, and missed hypernatremia risk in ICU and post-operative settings. The legacy term 'diabetes insipidus' remains widely used in patient communities and older literature, so the substrate names both — the new nomenclature is the going-forward standard, but patients should not be discouraged from using the term they learned at diagnosis. The disease driver is loss of arginine vasopressin production from the magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei, which release AVP from the posterior pituitary into the systemic circulation in response to plasma osmolality and volume signals. Without AVP, the renal collecting duct cannot insert aquaporin-2 channels in response to osmolar stimulus, free water is not reabsorbed, and the patient produces large volumes of dilute urine (often 5-15 L/day) with compensatory polydipsia. The critical danger is hypernatremia if access to water is restricted — in the elderly, the post-operative, the intubated, infants and children, or any patient with impaired thirst — where rapid dehydration becomes life-threatening within hours rather than days. Adipsic AVP-D (loss of thirst sensation from hypothalamic damage adjacent to the magnocellular nuclei) is a particularly dangerous subset, because the protective thirst response that keeps non-adipsic patients alive is absent; these patients require scheduled fluid intake and close electrolyte monitoring rather than 'drink to thirst.' Etiology shapes management. Post-pituitary-surgery is the most common iatrogenic cause, with a characteristic triphasic response pattern (transient AVP-D in the first few post-operative days from axonal injury and stunning, transient SIADH around day 5-10 from degenerating neuron AVP release, then permanent AVP-D if the magnocellular neurons cross a damage threshold). Traumatic brain injury with pituitary stalk transection causes similar pictures. Pituitary and hypothalamic tumors (craniopharyngioma is classic in pediatrics, germinoma in adolescents, metastases in older adults, lymphocytic infundibuloneurohypophysitis as an autoimmune cause) often produce stalk-thickening signal on MRI. Infiltrative diseases (Langerhans cell histiocytosis, sarcoidosis, IgG4-related hypophysitis, ROHHAD syndrome) cause variable AVP-D as part of broader hypothalamic-pituitary dysfunction. Congenital AVP gene mutations produce familial AVP-D presenting in childhood. Idiopathic AVP-D accounts for roughly 30% of cases. Diagnostic workup combines 24-hour urine output and osmolality measurement (low urine osmolality below 300 mOsm/kg in the face of polyuria), plasma sodium and serum osmolality, pituitary and hypothalamic MRI (looking for stalk thickening, mass, or absence of the posterior pituitary T1 hyperintense 'bright spot' — the characteristic AVP-D finding), and copeptin stimulation testing (which has displaced the historical water deprivation test as the modern preferred approach for ambiguous cases, with better sensitivity and reliability and without requiring the inpatient monitoring that water deprivation demands). Desmopressin is the load-bearing therapy. Available as oral tablets, oral disintegrating tablet, nasal spray, and subcutaneous or IV formulations for inpatient or special-circumstance use, dose is titrated to free water clearance — the goal is replacing enough AVP analog action to permit normal urine concentrating but not so much that the patient retains free water inappropriately and drifts toward hyponatremia. The 'drink to thirst' rule (rather than mandatory hydration) is the discipline that keeps sodium stable in non-adipsic patients; adipsic patients require scheduled intake and close monitoring. Pregnancy AVP-D has a physiologic variant — placental vasopressinase clears endogenous AVP, unmasking subclinical AVP-D or producing transient AVP-D of pregnancy — and desmopressin (vasopressinase-resistant) is the standard therapy through pregnancy. The community peptide candidates do not earn elevation here. BPC-157 doesn't engage posterior-pituitary biology or vasopressin replacement; its post-surgical 'healing peptide' framing collides directly with the most common AVP-D etiology (post-pituitary-surgery), where the underlying pathology was often a pituitary tumor and pro-angiogenic VEGF / eNOS signaling near a recently-operated sella is a category of risk no clinical algorithm endorses. NMN's general-aging NAD+ precursor pitch doesn't engage with osmoregulation, vasopressin synthesis, or AVP-D management at any level. The GH-axis peptides act on the anterior pituitary while AVP-D is posterior-pituitary biology — anatomically separate — but the AVP-D etiologies (post-pituitary-surgery, pituitary or hypothalamic tumor, infiltrative disease, post-radiation) frequently co-present with anterior pituitary hypofunction or known pituitary-tumor history, and the tesamorelin FDA label explicitly contraindicates pituitary tumor history. Treat the GH-axis class as one combined decision and recognize that for most AVP-D patients the underlying etiology functionally contraindicates the class. The editorial sensitivity here is real. AVP-D often arises post-pituitary surgery for prolactinoma, acromegaly, Cushing's disease, or craniopharyngioma — patients are recovering from neurosurgery and adjusting to lifelong replacement therapy with a peptide drug they will take for the rest of their lives. The hyponatremia danger is real and requires patient education that emphasizes restraint and discipline, not enthusiasm for layered interventions. This is the 57th deliberate non-elevation of community peptides, with the editorial distinction that the standard-of-care intervention IS itself a peptide therapy named explicitly in this entry rather than surfaced via the discovery hub. Resources: AMEND Australia, Diabetes Insipidus Foundation, Endocrine Society and ESE 2024 AVP-D guidelines, and the 2022 multi-society consensus nomenclature paper.